| 產(chǎn)品名稱 | L-NGC-alpha2B L-cells |
|---|---|
| 商品貨號 | B224198 |
| Organism | Mus musculus, mouse |
| Tissue | subcutaneous connective tissue; areolar and adipose |
| Product Format | frozen |
| Morphology | fibroblast |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | normal |
| Age | 100 days |
| Gender | male |
| Strain | C3H/An |
| Storage Conditions | liquid nitrogen vapor phase |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Images |  |
| Derivation | This line is a derivative of L-M(TK-) (see ATCC CCL-1.3) that is stably transfected with the gene for the human alpha2B adrenergic receptor. |
| Clinical Data | male |
| Receptor Expression | alpha 2B adrenergic, expressed |
| Comments | This line is a derivative of L-M(TK-) (see ATCC CCL-1.3) that is stably transfected with the gene for the human alpha2B adrenergic receptor. The cells express the human alpha2B adrenergic receptor protein. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subcultivation Ratio: 1:4 to 1:6 Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a Manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994. |
| Cryopreservation | Complete growth medium described above supplemented with 5% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Name of Depositor | Synaptic Pharmaceutical Corporation |
| Deposited As | Mus musculus |
| U.S. Patent Number | |
| References | Gluchowski C, et al. Use of alpha1C specific compounds to treat benign prostatic hyperplasia. US Patent 5,403,847 dated Apr 4 1995 Lagu B, et al. Morpholinone and morpholine derivatives and uses thereof. US Patent 6,531,471 dated Mar 11 2003 Gluchowski C, et al. Use of .alpha.1C specific compounds to treat benign prostatic hyperplasia. US Patent 6,602,888 dated Aug 5 2003 Cui D, et al. Dihydropyrimidines and uses thereof . U.S. Patent 6,680,323 dated Jan 20 2004 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
